JMDC Inc. (4483) AI Stock Analysis

• Market Cap: ¥300.60B
• Dividend Yield: 0.35%
• Average Volume (3M): 226.04K
• Price to Earnings (P/E): 48.5
• Beta (1Y): 0.86
• Revenue Growth: 29.09%
• EPS Growth: 87.01%
• Country: JP
• Employees: 1,773
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 14.79
• Shares Outstanding: 65,404,610
• 10 Day Avg. Volume: 228,330
• 30 Day Avg. Volume: 226,040
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ¥5,600.00
• Price Target Upside: 23.84% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 66 Neutral
• Price Target: ¥4,521.00 ▼(-0.02% Downside)

JMDC Inc. scores well due to its strong financial performance, characterized by consistent revenue growth and solid profitability margins. However, the high P/E ratio suggests potential overvaluation, and the technical indicators reflect a neutral market sentiment. The lack of earnings call data and corporate events limits further insights.

JMDC Inc. Business Overview & Revenue Model

Company Description

JMDC Inc. provides medical statistics data services in Japan. The company operates through three segments: Healthcare-Big Data, Telemedicine, and Dispensing Pharmacy Support. It offers medical field big data services; life insurance field big data services; support services for health insurance associations and local government health services; health data platform; and medical institution support services. The company also provides remote image interpretation matching services and ASP services for remote image interpretation system; and develops and sells business systems for dispensing pharmacies. It serves health insurance unions, pharmaceutical companies, life and non-life insurance companies, research institutions, etc. The company was incorporated in 2002 and is headquartered in Tokyo, Japan.

How the Company Makes Money

JMDC Inc. generates revenue primarily through its data services and analytics platforms. The company collects and analyzes large volumes of medical and health-related data, which it then sells to clients in the healthcare industry, such as pharmaceutical companies, insurance firms, and healthcare providers. Revenue streams include subscription fees for access to their data platforms, customized data analytics services, and IT solutions that help clients improve healthcare outcomes and operational efficiencies. Significant partnerships with healthcare institutions and continuous innovation in data technology also contribute to the company's earnings.

JMDC Inc. Financial Statement Overview

Summary

JMDC Inc. exhibits strong financial performance with consistent revenue growth and solid profitability margins. The balance sheet is stable with manageable leverage, although the recent decline in free cash flow growth warrants attention.

Income Statement

JMDC Inc. demonstrates strong revenue growth with a TTM increase of 5.52%, supported by healthy gross and net profit margins of 57.16% and 17.43%, respectively. The EBIT and EBITDA margins are robust at 20.94% and 27.63%, indicating efficient operational management. The company has consistently grown its revenue over the years, showcasing a positive growth trajectory.

Balance Sheet

The balance sheet reflects a stable financial position with a moderate debt-to-equity ratio of 0.60, indicating manageable leverage. The return on equity is decent at 9.88%, suggesting effective use of equity to generate profits. The equity ratio stands at 52.23%, highlighting a solid equity base relative to total assets.

Cash Flow

Cash flow analysis reveals a decline in free cash flow growth by 17.14% in the TTM, which could be a concern. However, the operating cash flow to net income ratio is healthy at 1.62, and the free cash flow to net income ratio is strong at 85.57%, indicating good cash generation relative to profits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.02B	41.72B	32.38B	27.81B	21.81B	16.77B
Gross Profit	24.65B	23.85B	19.25B	15.86B	12.59B	9.62B
EBITDA	12.06B	11.53B	9.23B	7.98B	6.51B	4.88B
Net Income	7.51B	7.28B	4.61B	4.27B	3.25B	2.48B
Balance Sheet
Total Assets	149.48B	143.02B	122.45B	98.57B	62.06B	57.85B
Cash, Cash Equivalents and Short-Term Investments	35.63B	32.18B	14.47B	22.78B	13.19B	19.90B
Total Debt	53.83B	46.89B	37.83B	20.40B	17.80B	19.45B
Total Liabilities	70.98B	64.54B	51.77B	34.04B	30.89B	29.60B
Stockholders Equity	78.05B	78.02B	70.59B	64.54B	31.18B	28.25B
Cash Flow
Free Cash Flow	10.41B	12.57B	-2.27B	2.12B	2.49B	952.00M
Operating Cash Flow	12.15B	14.69B	-17.00M	4.06B	3.81B	3.18B
Investing Cash Flow	-7.01B	-3.47B	-24.86B	-22.77B	-8.10B	-9.08B
Financing Cash Flow	12.62B	6.48B	16.58B	28.30B	-2.41B	18.11B

JMDC Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 4522.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4483, the sentiment is Neutral. The current price of 4522 is above the 20-day moving average (MA) of 4427.00, above the 50-day MA of 4229.86, and above the 200-day MA of 3647.01, indicating a neutral trend. The MACD of 102.86 indicates Positive momentum. The RSI at 50.17 is Neutral, neither overbought nor oversold. The STOCH value of 28.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4483.

JMDC Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
3649	79 Outperform	21.85B	18.10	―	1.88%	-6.29%	-22.25%
2175	72 Outperform	135.46B	19.05	12.79%	1.81%	10.66%	0.41%
4483	66 Neutral	¥300.60B	48.45	―	0.35%	29.09%	87.01%
4480	60 Neutral	82.23B	56.58	13.85%	―	34.77%	-46.50%
3902	43 Neutral	23.24B	-31.76	―	1.09%	-0.58%	-260.22%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

JMDC Inc. Corporate Events

JMDC Inc. Reports Strong Q1 2025 Financial Growth

JMDC Inc. reported significant financial growth for the first quarter ending June 30, 2025, with a 32.5% increase in revenue and a 48.8% rise in operating profit compared to the same period last year. This growth reflects the company’s strategic focus on its core operations after discontinuing its dispensing pharmacy support business, enhancing its market positioning and potentially increasing shareholder value.

JMDC Inc. Finalizes Share Subscription Rights for Employees and Directors

JMDC Inc. has finalized the details of share subscription rights to be issued to its directors, executive officers, and employees, as well as those of its subsidiaries. This move, decided in a board meeting on June 25, 2025, involves the issuance of 6,840 share subscription rights, allowing for the exercise of 684,000 common shares, potentially impacting the company’s equity structure and aligning employee interests with corporate growth.

JMDC Inc. Announces OMRON as New Parent Company

JMDC Inc. has announced that OMRON Corporation has become its new parent company after acquiring a majority stake through a tender offer. Despite this change, JMDC maintains operational independence with no business dependence on OMRON, ensuring protection for minority shareholders in any potential transactions.

JMDC Inc. Issues Share Subscription Rights to Boost Growth and Talent Retention

JMDC Inc. announced the issuance of share subscription rights to its directors, executive officers, and employees, as well as those of its subsidiaries, to enhance motivation and attract talent. This move is part of JMDC’s strategy to expand its business and achieve medium-term goals, ultimately enhancing corporate and shareholder value while maintaining reasonable share dilution.